SwanBio Therapeutics, Inc.

SwanBio Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies for rare genetic diseases. Their advanced treatments aim to address critical health challenges and improve patient outcomes through targeted therapies. SwanBio Therapeutics, Inc.

specializes in gene therapies for rare genetic diseases. Founded in 2018 in the US, the company has undergone strategic shifts since its inception. The founders, Florian Eichler, Karen Kozarsky, and Rachel Salzman, have backgrounds in biotechnology and have been involved in multiple ventures. The company raised USD 56.

00 mn in Series B funding on May 18, 2022, with participation from Mass General Brigham Ventures and Syncona Limited, marking a significant milestone in its fundraising history. This funding represents the total amount raised by the company to date, with three known deals. SwanBio Therapeutics develops groundbreaking gene therapies for conditions such as Gaucher disease, Parkinson's disease, and various forms of dementia. Their core product offerings are designed to enhance gene expression and aim to provide transformative results with a single dose.

Targeting the North American and European healthcare markets, SwanBio focuses on partnerships with hospitals and specialized providers to improve treatment options for patients with chronic diseases. Their mission is to redefine care standards in gene therapy, aligning with the needs of patients and healthcare professionals. SwanBio Therapeutics' revenue model is based on strategic partnerships and collaborations with healthcare institutions. The company engages in business-to-business relationships, negotiating pricing arrangements for their therapies aimed at conditions like Gaucher disease and Parkinson's.

Revenue is generated through transactional agreements for clinical use of their gene therapy products, ensuring that healthcare providers can access their innovative treatments effectively. SwanBio Therapeutics plans to leverage the recent USD 56. 00 mn Series B funding to advance the clinical development of SBT101. The company is focused on launching new products tailored for treating debilitating conditions, with specific timelines and details yet to be disclosed.

Additionally, SwanBio aims to expand its reach within North America and Europe, solidifying its presence in regions with a high demand for innovative gene therapies. This growth strategy will be supported by the recent funding to enhance clinical trials and product development.